Sussex Formulary
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
    • Sussex-wide protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
    • 2025
    • 2024
    • 2023
  • APC Minutes
    • 2021
    • 2022
    • 2023
    • 2024
    • 2025
    • 2026
  • Discontinuations
  • Contact us
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
      • 3.1 Airways disease, obstructive
      • 3.2 Allergic conditions
        • 3.2.1 Angioedema
        • 3.2.2 Antihistamines
        • 3.2.3 Allergen Immunotherapy
        • 3.2.4 Omalizumab, mepolizumab and other therapies
      • 3.3 Conditions affecting sputum viscosity
      • 3.4 Cough and congestion
      • 3.5 Interstitial lung disease
      • 3.6 Respiratory depression, respiratory distress syndrome and apnoea
      • 3.7 Other Respiratory system items
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
  • APC Minutes
  • Discontinuations
  • Contact us
  • Search

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Chlorphenamine

Over the Counter { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

OTC Policy statement

Chlorphenamine 4mg tablets

Pack
28 tablet
30 tablet
1000 tablet
500 tablet
60 tablet
100 tablet

Chlorphenamine 2mg/5ml oral solution

Pack
150 ml

Chlorphenamine 2mg/5ml oral solution sugar free

Pack
150 ml

Chlorphenamine 10mg/1ml solution for injection ampoules

Pack
5 ampoule

Hydroxyzine

{ Value = MHRA Warning Exists, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Hydroxyzine 10mg tablets

Pack
84 tablet

Hydroxyzine 25mg tablets

Pack
28 tablet
25 tablet

Promethazine hydrochloride

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

For sedation

Promethazine 5mg/5ml oral solution sugar free

Pack
100 ml

Promethazine hydrochloride 10mg tablets

Pack
56 tablet
16 tablet

Promethazine hydrochloride 25mg tablets

Pack
56 tablet
14 tablet
10 tablet
30 tablet
100 tablet

Promethazine 25mg/1ml solution for injection ampoules

Pack
10 ampoule

Online Formulary by M.O.M. Systems

NICE guidance is available from https://www.nice.org.uk/guidance All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

© Copyright 2026